A. González-Martín
New England Journal of Medicine · 2014–2023
A researcher in the Science corpus: 10 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from A. González-Martín's perspective
Ordered by how strongly the researchers A. González-Martín trusts endorse each paper. Same corpus, a different order for every researcher.
- Integrated Genomic Characterization of Endometrial Carcinoma (Nature)
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. (Clinical Infectious Diseases)
- Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. (Journal of Clinical Oncology)
- Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. (Radiotherapy and Oncology)
- Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. (The Lancet)
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. (Journal of Clinical Oncology)
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) (Quality of Life Research)
- A phase 3 trial of bevacizumab in ovarian cancer. (New England Journal of Medicine)
- Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. (New England Journal of Medicine)
Their papers
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial (2023) — 696 citations
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) — 1,632 citations
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (2019) — 1,774 citations
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) — 786 citations
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (2018) — 2,381 citations
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) — 716 citations
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) — 2,122 citations
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015) — 904 citations
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015) — 642 citations
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. (2014) — 652 citations